DiaMedica Therapeutics financials
$8.20−1.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | $500.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | $500.0K |
| Gross margin | — | — | — | — | — | — | — | 100.0% |
| Operating income | -$34.4M | -$26.7M | -$21.3M | -$14.0M | -$13.6M | -$12.7M | -$11.6M | -$6.8M |
| Net income | -$32.7M | -$24.4M | -$19.4M | -$13.7M | -$13.6M | -$12.3M | -$10.6M | -$5.7M |
| Net margin | — | — | — | — | — | — | — | −1146.8% |
| Diluted EPS | $-0.70 | $-0.60 | $-0.60 | $-0.52 | $-0.65 | $-0.78 | $-0.89 | $-0.74 |
| EBITDA | -$34.4M | -$26.6M | -$21.2M | -$14.0M | -$13.6M | -$12.7M | -$11.6M | -$6.7M |
| Operating cash flow | -$29.1M | -$22.1M | -$18.7M | -$11.5M | -$12.3M | -$9.2M | -$9.1M | -$5.7M |
| Free cash flow | -$29.1M | -$22.1M | -$18.8M | -$11.6M | -$12.3M | -$9.2M | -$9.1M | -$5.7M |
| Diluted shares | 47.0M | 40.4M | 32.6M | 26.4M | 20.8M | 15.7M | 12.0M | 7.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.6M | $3.0M | $4.5M | $4.7M | $4.7M | $7.4M |
| Short-term investments | $44.2M | $41.1M | $48.4M | $28.8M | $40.4M | $20.1M |
| Total debt | $15.0K | $25.0K | $4.0K | $10.0K | $45.0K | $13.0K |
| Total assets | $61.4M | $46.3M | $54.2M | $34.4M | $45.6M | $28.1M |
| Total liabilities | $5.3M | $5.6M | $3.1M | $2.6M | $1.5M | $2.1M |
| Shareholders' equity | $56.1M | $40.7M | $51.1M | $31.8M | $44.0M | $26.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology